Core Viewpoint - Sanofi Bio announced that the first lock-up period of its third employee stock ownership plan will expire on November 13, 2025, allowing for the release of 375,000 shares, which represents 12.50% of the total shares in this plan [2] Summary by Relevant Sections - Employee Stock Ownership Plan - The total number of shares in the third employee stock ownership plan is 3,000,000 shares [2] - Upon expiration of the first lock-up period, 375,000 shares will be unlocked, accounting for 0.07% of the company's total share capital [2]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-082 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于第三期员工持股计划第一个锁定期届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）分别于 2024 年 1 月 2 日、 2024 年 1 月 19 日召开第五届董事第八次会议、第五届监事会第八次会议和 2024 年第一次临时股东大会，审议并通过《关于〈三诺生物传感股份有限公司第三期 员工持股计划（草案）〉及其摘要的议案》《关于〈三诺生物传感股份有限公司第 三期员工持股计划管理办法〉的议案》《关于提请股东大会授权董事会办理第三 期员工持股计划相关事宜的议案》；于 2024 年 4 月 24 日召开第五届董事会第十 次会议，审议并通过《关于〈三诺生物传感股份有限公司第三期员工持股计划（草 案修订稿）〉及其摘要的议案》，具体内容详见公司于 2024 年 1 月 4 日、2024 年 1 月 1 ...

Core Insights - The trend of "sugar control" has emerged as a new lifestyle choice, with increasing public interest in blood sugar management and its impact on health [1][2][4] - The popularity of continuous glucose monitors (CGMs) has surged among young people, transforming from a medical device for diabetes patients to a fashionable health accessory [5][14][33] Group 1: Market Trends - Discussions on social media regarding "blood sugar," "sugar control," and "blood sugar and weight" remain highly active, indicating a growing awareness and concern [2][9] - In the past 90 days, there have been approximately 51,800 posts related to sugar control on platforms like Xiaohongshu, nearly matching the number of posts about weight loss meals [3] - The number of early-onset type 2 diabetes patients aged 15-39 in China has increased from 9.61 million in 1990 to 23.74 million in 2021, a 147% rise over 31 years [9][10] Group 2: Consumer Behavior - Young consumers are increasingly curious about their blood sugar levels, leading to a habit of checking real-time blood sugar data after meals [7][8] - The use of CGMs allows individuals to monitor the effects of various foods on their blood sugar, leading to more informed dietary choices [11][19] - The trend of using CGMs is not unique to China; similar communities have formed in Western markets, where sharing data has become a health fashion [13][14] Group 3: Product Development - The demand for CGMs has prompted manufacturers to focus on making devices smaller, more user-friendly, and capable of seamless integration into daily life [24][25] - Leading brands are enhancing their products with features like 24-hour monitoring, real-time data synchronization, and personalized health management services [26][27][30] - The introduction of policies and subsidies has made CGMs more accessible, contributing to their popularity among younger demographics [30][31] Group 4: Cultural Shift - The perception of health management is shifting from a reactive approach to a proactive one, with young people embracing the idea of "preventive health" [33][34] - CGMs have evolved from being seen as medical tools to becoming symbols of a healthy lifestyle, with users openly sharing their experiences and data on social media [33][36] - This cultural change reflects a broader understanding that health is not merely the absence of illness but an active pursuit of well-being [34][35]

Core Insights - The company reported its Q3 2025 results, showing a revenue of 3.453 billion yuan, an 8.52% year-on-year increase, but a net profit decline of 17.36% to 211 million yuan [1] - The significant drop in net profit was primarily due to patent licensing fees impacting the financials, with a specific charge of 19 million USD affecting Q3 net profit by approximately 136 million yuan [2] - The company continues to expand its Continuous Glucose Monitoring (CGM) product line, achieving significant sales growth and global market penetration [2] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 34.53 billion yuan, with a net profit of 2.11 billion yuan, reflecting a year-on-year decrease [1] - In Q3 2025, revenue reached 1.19 billion yuan, marking a 13.40% increase, while net profit fell to 30 million yuan, a 47.55% decline [1][2] - Excluding the impact of patent fees, the adjusted net profit for Q3 would have been 1.05 billion yuan, representing an 82% year-on-year growth [2] Product Development and Market Strategy - The second-generation CGM product received EU CE MDR certification in July 2025, featuring improved design for user comfort and convenience [2] - The company is exploring a new model integrating "biosensing + artificial intelligence + healthcare," aiming to enhance clinical decision-making through comprehensive data support [3] - The launch of the "Ai Kan Health" app is part of the strategy to leverage AI for customer service and data analysis, enhancing operational efficiency [3] Market Challenges - Ongoing patent disputes have temporarily affected the sales of the first-generation iCanCGM product in certain European markets, although the second-generation product remains unaffected [3] - The company faces potential risks related to overseas sales performance and increasing market competition [4]

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company's performance met expectations, with revenue growth accelerating. In Q3 2025, the company reported revenue of 1.19 billion yuan, a year-on-year increase of 13.40%. However, the net profit attributable to shareholders decreased by 47.55% to 30 million yuan, primarily due to patent licensing fees impacting profits. Excluding this effect, the net profit would have been 105 million yuan, reflecting an 82% year-on-year increase [2][11]. - For the first three quarters of 2025, the company achieved a revenue of 3.453 billion yuan, up 8.52% year-on-year, while the net profit attributable to shareholders was 211 million yuan, down 17.36% [6][11]. - The sales of Continuous Glucose Monitoring (CGM) products continue to grow, supported by a global expansion strategy. The second-generation CGM product received EU CE MDR certification in July 2025, enhancing user convenience and comfort [11]. - The company is exploring a new model combining "biosensing + artificial intelligence + healthcare," aiming to provide comprehensive data support for clinical decision-making through its "AiKan Health" app [11]. - Profit forecasts indicate that the company, as a leader in blood glucose monitoring, is expected to achieve net profits of 388 million, 484 million, and 611 million yuan for 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 27, 22, and 17 [11]. Financial Summary - In Q3 2025, the company's revenue was 1.19 billion yuan, with a net profit of 30 million yuan. The net profit for the first three quarters was 211 million yuan, with a revenue of 3.453 billion yuan [2][6]. - The company’s total revenue for 2024 is projected at 4.443 billion yuan, with a net profit of 326 million yuan, and is expected to grow to 6.320 billion yuan and 611 million yuan by 2027 [16].

Group 1 - Sanofi Biologics has made significant progress in a project that integrates artificial intelligence technology to enhance the stability of enzyme preparations [1] - The company is establishing a new R&D center in Changsha, Hunan, which will focus on developing biosensors, wearable devices, and high-end implantable medical devices, set to be operational by the end of this year [1] - The concentration of R&D efforts in Changsha is expected to accelerate innovation and product development [1] Group 2 - Changsha is enhancing its public innovation platform, focusing on advanced computing and artificial intelligence, as well as biomedical fields, with the establishment of key laboratories [2] - The city has signed deep cooperation agreements with local universities to promote industry-university-research collaboration, facilitating technological innovation [2] - Changsha has built 18 technology transfer bases and 10 intellectual property transformation centers in collaboration with universities and research institutions [2] Group 3 - Changsha is optimizing its development environment to stimulate innovation, with a focus on the biomanufacturing sector [3] - A professor from Central South University has successfully commercialized over 130 independent intellectual property rights through a startup, applying technology to more than 20 companies [3] Group 4 - The city has seen a significant increase in technology contract transaction volume, surpassing 100 billion yuan, reaching 109.528 billion yuan this year [4] - The number of technology-based small and medium-sized enterprises in Changsha has exceeded 10,000 for the first time, totaling 11,700 [4]

Group 1 - Sanofi Biologics has made significant progress in a project that integrates artificial intelligence technology to enhance the stability of enzyme preparations [1] - The company is establishing a new R&D center in Changsha, Hunan, which will focus on developing biosensors, wearable devices, and high-end implantable medical devices, set to be operational by the end of this year [1] - The concentration of R&D efforts in Changsha is expected to accelerate innovation and product development [1] Group 2 - Changsha is enhancing its public innovation platform, focusing on advanced computing and artificial intelligence, as well as biomedical fields, with the establishment of key laboratories [2] - The city has signed deep cooperation agreements with local universities to promote industry-academia collaboration, facilitating technology innovation [2] - Changsha has built 18 technology transfer bases and 10 intellectual property transformation centers to support innovation [2] Group 3 - The city is optimizing its development environment to stimulate innovation, with a focus on the biomanufacturing sector [3] - A professor from Central South University has successfully commercialized over 130 independent intellectual property rights through a startup, applying technology to more than 20 companies [3] Group 4 - The government has facilitated connections between academic research and market needs, enabling efficient technology transfer within the innovation park [4] - Changsha's technology contract transaction volume has exceeded 100 billion yuan, reaching 109.528 billion yuan this year, indicating a robust innovation ecosystem [4] - The number of technology-based small and medium-sized enterprises in Changsha has surpassed 10,000, totaling 11,700 [4]

Core Viewpoint - Sanofi Bio showcased its new generation Continuous Glucose Monitoring System (CGM) at the 8th China International Import Expo, highlighting its advancements in diabetes digital management [1][3]. Group 1: Product Innovations - The Sanofi Aikan CGM is based on third-generation glucose sensing technology, reducing product size by 60%, enhancing comfort and concealment [3]. - The sensor's accuracy has reached international leading levels, with improved anti-interference performance and a battery life extended to 15 days, providing a comprehensive glucose fluctuation profile [3]. - The product has received EU CE-MDR certification and is currently pursuing FDA registration in the U.S. [3]. Group 2: Market Strategy - Sanofi Bio has integrated Trividia to leverage its established brand and channel resources, successfully entering mainstream retail systems like Walmart and Amazon [4]. - The company exports an average of 40,000 devices monthly to over 40 countries in Africa, targeting both grassroots healthcare and home users [4]. - Sanofi Bio ranks as the fourth largest blood glucose meter company globally and holds the top position in the Chinese market [4]. Group 3: Collaborative Ecosystem - Sanofi Bio participated in the Sanofi Type 1 Diabetes Ecosystem Cooperation Forum, discussing new diabetes management ecosystems with representatives from various sectors [4]. - The company emphasizes a multi-party collaboration model involving government, industry, academia, healthcare, and investment to create a sustainable diabetes management ecosystem [4][5]. - The integration of rapid testing capabilities, continuous data collection, and personalized analysis through the SinoGPT AI system aims to cover the entire diabetes management process from screening to long-term management [5]. Group 4: Future Vision - Sanofi Bio aims to become a global leader in diabetes digital management, focusing on innovation in medical technology to enhance health outcomes across diverse demographics [5].

Group 1 - The company actively participates in government centralized procurement for blood glucose test strips, focusing on regional projects [2] - Currently, the company has successfully implemented five procurement projects across 62 cities in 13 provinces nationwide [2] - The company aims to enhance its market competitiveness by improving product quality control, optimizing production costs, and enhancing sales services [2]

Core Insights - Novo Nordisk announced a comprehensive upgrade of its "Health Ecosystem Alliance" at the 8th China International Import Expo, transitioning from a singular focus on digital healthcare to a collaborative cross-industry approach [1] Group 1: Digital Health Ecosystem - The "Health Ecosystem Alliance" aims to establish an "online + offline" intelligent chronic disease management network, integrating data from doctors, pharmaceutical companies, and medical devices to create a sustainable closed loop [2] - The alliance has partnered with major health platforms like Alibaba Health, JD Health, and Tencent Health to build a digital chronic disease management ecosystem, emphasizing early screening, diagnosis, and treatment [2] Group 2: Device Connectivity and Data Integration - Novo Nordisk will collaborate with Weitai Medical and Yuyue Medical to integrate insulin pen and dynamic blood glucose meter data, enabling visualized management of blood glucose and medication for patients [3] - The partnership with Huawei Health will incorporate exercise and heart rate data into the "Novo Care" platform, creating a comprehensive health profile for users [3] Group 3: Product Launches - The launch of the Harmony version of the "Novo Care" app, compatible with Huawei devices, and the weight management version focuses on providing customized health management solutions for diabetes, rare diseases, and obesity [4] - The new app versions aim to enhance user experience by offering features like disease education, smart medication guidance, and a "pharmacy map" [4] Group 4: Patient-Centric Approach - Novo Nordisk's senior vice president emphasized that digital innovation is reshaping chronic disease management, aiming to create a future-oriented health service model through collaboration with leading digital ecosystem partners in China [5] - The company's goal extends beyond drug innovation to enhancing public health literacy and supporting the "Healthy China" strategy through digital services [5]